Ashkan M. Abbey, MD, FASRS, FAAO, of Texas Retina Associates in Dallas, moderated a recent Modern Retina Case-Based Roundtable on diagnosing and treating patients with macular telangiectasia type 2 ...
Discover key insights from the AAO 2025 meeting, highlighting advancements in real-world data, gene therapies, multitargeting treatments, and AI in retina care. This year in retina is almost ...
Panelists discuss how aflibercept’s structural design and the higher molar dose of its 8-mg formulation enhance VEGF binding, treatment durability, and clinical predictability. The panel reviews why ...
A panelist discusses how careful timing, patient education, and bilateral treatment planning strengthen real-world NT-501 management for MacTel type 2. A panelist discusses how key takeaways from ...
Catch up on this week's highlights in retina. Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
DURAVYU is being developed as a potential sustained-delivery treatment for patients suffering from serious retinal diseases. EyePoint Pharmaceuticals has released details for its pivotal phase 3 ...
The EURETINA meeting featured new treatments in gene therapy and innovative implants to enhance patient quality of life. Frank Holz, MD, FEBO, FARVO, a retina specialist from Bonn, Germany, discusses ...
At the EURETINA congress, Prof Pollreisz shared his contemporary approach to multimodal imaging in patients with diabetes. This year, the European Society of Retina Specialists (EURETINA) held its ...
During the EURETINA session, Stela Vujosevic, MD, PhD, FEBO, posed questions about the current staging for diabetic macular edema and diabetic retinopathy. As imaging modalities improve, so do ...
Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa. Beacon Therapeutics recently revealed topline data ...
In her keynote address, Prof Schmidt-Erfurth focused on new artificial intelligence tools and their usage in addressing age-related macular degeneration. At this year's meeting of the European Society ...
In recent years, gene therapy has emerged from the shadows of theoretical potential into the spotlight of clinical reality. The approval of voretigene neparvovec-rzyl (Luxturna) marked a historic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results